Studies identified after excluding duplications. by Nader Muthanna (20496266)

Characteristics of included studies. by Nader Muthanna (20496266)

Completed risk of bias assessments. by Nader Muthanna (20496266)

All data extracted in primary studies. by Nader Muthanna (20496266)

PRISMA statement 2020 flow diagram. by Nader Muthanna (20496266)

Certainty of evidence according to GRADE. by Nader Muthanna (20496266)

The funnel plot of publication bias. by Nader Muthanna (20496266)

Risk of bias assessment. by Nader Muthanna (20496266)

List of DEGs via FC values. by Zi-Yun Yi (19859589)

“…Even though, there was no significant difference in the number of eggs ovulated by the TSD mice compared to the control groups. …”

Weight and plasma biochemistry. by Søren Egstrand (10906087)

“…<div><p>Secondary hyperparathyroidism (sHPT) is a significant clinical complication of CKD leading to bone abnormalities and cardiovascular disease. …”

End-systolic pressure–volume loop relationship slope during CPR. by Woo Jin Jung (3279570)

Summary of adverse reactions. by Qiang Yang (135832)

“…Oral theophylline could be a supplementary therapeutic option when inhaled therapy is insufficient regarding of improvement in pulmonary function and reducing in exacerbation risk. …”

Funnel plot of exacerbation rate. by Qiang Yang (135832)

“…Oral theophylline could be a supplementary therapeutic option when inhaled therapy is insufficient regarding of improvement in pulmonary function and reducing in exacerbation risk. …”

This S1 File is the date set used for this study. by Menberu Gete (21273355)

Table of the risk of bias by Qiang Yang (135832)

“…Oral theophylline could be a supplementary therapeutic option when inhaled therapy is insufficient regarding of improvement in pulmonary function and reducing in exacerbation risk. …”

Data extracted from the primary research by Qiang Yang (135832)

“…Oral theophylline could be a supplementary therapeutic option when inhaled therapy is insufficient regarding of improvement in pulmonary function and reducing in exacerbation risk. …”

Summary of the risk of bias. by Qiang Yang (135832)

“…Oral theophylline could be a supplementary therapeutic option when inhaled therapy is insufficient regarding of improvement in pulmonary function and reducing in exacerbation risk. …”

List of all 594 sources screened by Qiang Yang (135832)

“…Oral theophylline could be a supplementary therapeutic option when inhaled therapy is insufficient regarding of improvement in pulmonary function and reducing in exacerbation risk. …”

Basic characteristics of included articles. by Qiang Yang (135832)

“…Oral theophylline could be a supplementary therapeutic option when inhaled therapy is insufficient regarding of improvement in pulmonary function and reducing in exacerbation risk. …”

Numbered table of all studies by Qiang Yang (135832)

“…Oral theophylline could be a supplementary therapeutic option when inhaled therapy is insufficient regarding of improvement in pulmonary function and reducing in exacerbation risk. …”